This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
About the interviewee Imran Khan, MD, PhD is Vice President Medical Affairs, Hematology at Johnson & Johnson Innovative Medicine. Most recently, Imran has served as MedicalScience Liaison (MSL) Head, Oncology U.S. Medical Affairs. CAR T Cells: Engineering Immune Cells to Treat Cancer [Internet]. Cancer.gov.
Human Xtensions, founded as a result of this idea, thanks to its multi-disciplinary team of engineers, created the unique HandX system. ” An attractive proposition in a world in which technology has contributed significantly to the distancing of physicians from their patients, usually leading to negative sideeffects.
BTKis, oral drugs given as continuous monotherapy, have revolutionised the treatment of CLL, with the first generation BTKi ibrutinib receiving European Medicines Agency (EMA) approval in 2014; however, side-effects (such as cardiovascular toxicities 2 ) have limited its suitability. BioMedical Engineering Online. 2022; 21(1).
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Engineering 
110 
Let's personalize your content